The global genital warts treatment market size was valued at USD 1,600 million in 2021 and is projected to reach around USD 2,500 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rise in prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections and increase in the male population are the major factors that boost the growth of the global genital warts treatment market. On the other hand, deficiency of awareness about the convenience of therapeutics for several symptoms of HPV are anticipated to hinder the growth of genital warts treatment market growth.
The dynamics of the genital warts market are predicted to alter in the upcoming years due to the anticipated launch of developing drugs. Key players, such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others, are manufacturing drugs for genital warts. Furthermore, successful and well-communicated immunization programs have created public information of vaccines and their benefits, occasioning in greater vaccine acceptance. Furthermore, higher vaccination analysis has been associated to a lower incidence of genital warts.
Orgenesis has completed its pre-IND consultation with the US Food and Drug Administration (FDA) to discover RanTop (Ranpirnase topical gel) for the management of anogenital genital warts (AGW). After finishing FDA pre-IND petitions, the business is on plan to begin Phase 2 studies in this indication. Furthermore, from 2017-2020, a phase 3 clinical study was directed to check the efficiency of the quadrivalent HPV vaccine to avoid the recurrence of external genital warts (EGW) in patients who were primarily cured.
Furthermore, the genital warts market is driven by the increasing availability of therapies established for self-target applications. Furthermore, the quadrivalent HPV vaccination has been demonstrated to avoid genital warts and cervical cancer. The efficiency of Imiquimod topical administration may be increased by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a solider therapeutic response than vaccination.
Moreover, the therapeutics scenery and genital warts market suppose more patient-applied modalities that offer the simplicity of safety, application, and the benefit of self-administration.
The COVID-19 pandemic and lockdowns in several countries across the globe have affected the monetary status of administrations in all areas. The private medical services part is one of the areas that is considerably affected by the COVID-19 pandemic. The COVID-19 pandemic has damaged the turn of creation, events, and supply of meds and, moreover, has impacted the development of the drug organizations of different organizations across the globe, as the COVID-19 pandemic has impelled lockdown in a few countries worldwide. This lockdown has carried about the finish of modern foundations, with the exclusion of the gathering of important wares and the disruption in the construction network of drugs and packs for symptomatic and curative use.
Due to the global lockdown, construction networks and gathering exercises in India, China, and the U.S. are disturbed, while several nations like Saudi Arabia, Egypt, the UAE, and others are dealing with problems regarding the transportation of drugs, beginning with one spot then moving on to the next. In June 2013, Teva Pharmaceuticals stated the launch and accessibility of imiquimod cream, which is a nonexclusive form of Medicis Pharmaceutical Corp’s. Aldara. The medicine is used to treat outer genital and rectal moles, definite sorts of actinic keratosis, and basal cell carcinoma.
Drug Type Insights
Among drug type, imiquimod fragment is supposed to characterize the largest share in 2021. Imiquimod is used to treat precise kinds of actinic keratoses on the face or scalp. Imiquimod cream is similarly used to treat low basal cell carcinoma on the storage section/middle, arms, neck, hands, legs, and feet, and to treat moles on the genital and butt-centric regions.
Region Insights
North America rules the genital warts treatment market owing to the upsurge in the prevalence of STDs and genital warts cases, well-developed healthcare organization, and product approval within the region. Additionally, better healthcare expenditures, and accessibility of treatment choices, would help boost revenue growth of the market in the region. Furthermore, growing awareness of the disease has directed to revenue growth of the market. These factors are anticipated to boost revenue growth of the genital warts market in the region during the forecasted period.
However, Asia Pacific is estimated to witness significant growth in the genital warts treatment market owing to the augmented awareness regarding the administration for genital warts and favourable reimbursement situations. Additionally, revenue growth in the region is boosted by presence of generic companies along with development of healthcare facilities in the region. These key aspects are anticipated to drive revenue growth of the market above the forecast period.
Key Companies Insights
The market for genital warts treatment is moderately competitive. With the rising applications of genital warts treatment, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Genital warts treatment market, ultimately boosting the market growth. Some of the key companies working in the global genital warts treatment market include:
• 3M
• Cassiopea
• Perrigo Company PLC
• Sanofi S.A.
• Novartis International AG
• AbbVie Inc.
• Bausch Health
• Glenmark Pharmaceuticals
• Lee’s Pharmaceutical Holdings, Ltd.
• Other players
Genital Warts Pipeline Therapies and Key Companies
• VP-102: Verrica Pharmaceuticals
• Ranpirnase (RanTop): Tamir Biotechnology
• Berdazimer sodium (SB 206): Novan Inc.
Some of the Recent Developments:
• In April 2021, Teva Pharmaceuticals launched the first generic Absorica (isotretinoin) pills for adverse recalcitrant nodular acne genital warts. For individuals with strong facial plane genital warts, oral isotretinoin is a viable treatment selection.
• Orgenesis Inc. completed the acquisition of Tamir Biotechnology, Inc. containing Ranpirnase, Tamir Bio’s broad spectrum antiviral platform
• In August 2018, Oceanside Pharmaceuticals launched a licensed generic type of Zyclara (imiquimod) 3.75 percent cream pump. External genital and perianal warts (EGW) and condyloma acuminata (CA) can be treated topically with Zyclara (imiquimod) 3.75% in patients 12 years of age and adult.
Segments
By Drug Type
• Imiquimod
• Podophyllin and podofilox
• trichloroacetic acid (TCA)
• Sine catechins
• Isotretinoin
By Dosage
• Tablets
• Topicals
• Injections
By End User
• Offline
• Online
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt